Literature DB >> 15249202

Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.

Mark S Duxbury1, Hiromichi Ito, Michael J Zinner, Stanley W Ashley, Edward E Whang.   

Abstract

The Eph tyrosine kinases interact with ligands of the Ephrin family and have diverse cellular functions. EphA2 has been recognized to be an oncoprotein of importance in a range of cancers. Here, we examine the effect of EphA2 overexpression and ligation by chimeric Ephrin A1-Fc on the invasive phenotype of pancreatic adenocarcinoma cells. We show that EphA2 overexpression induces a FAK-dependent increase in MMP-2 expression and invasiveness. EphA2 ligation induces proteosomal degradation of EphA2, attenuates the invasive phenotype, and decreases both FAK phosphorylation and MMP-2 expression. EphA2 appears to represent a rational therapeutic target and ligation by Ephrin A1-Fc is one strategy to modulate levels of this oncoprotein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249202     DOI: 10.1016/j.bbrc.2004.06.054

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  48 in total

1.  Quantitative phosphotyrosine proteomics of EphB2 signaling by stable isotope labeling with amino acids in cell culture (SILAC).

Authors:  Guoan Zhang; Daniel S Spellman; Edward Y Skolnik; Thomas A Neubert
Journal:  J Proteome Res       Date:  2006-03       Impact factor: 4.466

2.  Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis.

Authors:  Balasubramaniam Annamalai; Xueguang Liu; Udhayakumar Gopal; Jennifer S Isaacs
Journal:  Mol Cancer Res       Date:  2009-06-30       Impact factor: 5.852

3.  Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.

Authors:  Carla M Lema Tomé; Enzo Palma; Sara Ferluga; W Todd Lowther; Roy Hantgan; Jill Wykosky; Waldemar Debinski
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

4.  EphA2 signaling following endocytosis: role of Tiam1.

Authors:  Pomme Boissier; Jin Chen; Uyen Huynh-Do
Journal:  Traffic       Date:  2013-10-10       Impact factor: 6.215

5.  Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma.

Authors:  Xia Li; Li Wang; Jian-Wen Gu; Bing Li; Wei-Ping Liu; Yan-Gang Wang; Xiang Zhang; Hai-Ning Zhen; Zhou Fei
Journal:  Tumour Biol       Date:  2010-06-23

Review 6.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

7.  Targeted delivery of YSA-functionalized and non-functionalized polymeric nanoparticles to injured pulmonary vasculature.

Authors:  Madhoosudan A Patil; Arun K Upadhyay; Laura Hernandez-Lagunas; Ryan Good; Todd C Carpenter; Carmen C Sucharov; Eva Nozik-Grayck; Uday B Kompella
Journal:  Artif Cells Nanomed Biotechnol       Date:  2018-11-19       Impact factor: 5.678

8.  Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.

Authors:  J Jehle; I Staudacher; F Wiedmann; Pa Schweizer; R Becker; Ha Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

9.  Clinical implications of EphB4 receptor expression in pancreatic cancer.

Authors:  Man Li; Zuowei Zhao
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

10.  Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma.

Authors:  Constantinos Giaginis; Gerasimos Tsourouflis; Adamantia Zizi-Serbetzoglou; Gregorios Kouraklis; Elli Chatzopoulou; Konstantina Dimakopoulou; Stamatios E Theocharis
Journal:  Pathol Oncol Res       Date:  2009-12-01       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.